Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-01-01
2008-01-01
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C436S501000, C530S300000, C530S350000, C424S130100, C424S178100
Reexamination Certificate
active
07314717
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.
REFERENCES:
patent: 4444879 (1984-04-01), Foster et al.
patent: 5062935 (1991-11-01), Schlag et al.
patent: 5538897 (1996-07-01), Yates, III et al.
patent: 5849297 (1998-12-01), Harrison et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: 6221657 (2001-04-01), Harrison et al.
patent: 6268485 (2001-07-01), Farries et al.
patent: WO 87/06344 (1987-10-01), None
patent: WO 90/14148 (1990-11-01), None
patent: WO 91/13352 (1991-09-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/07036 (1998-02-01), None
patent: WO 98/32390 (1998-07-01), None
patent: WO 00/49410 (2000-08-01), None
patent: WO 01/05422 (2001-01-01), None
Tang, et al., “Contribution of Renal Secreted Completed C3 to the Circulating Pool in Humans1”, Journal of Immunology (1999), vol. 162, No. 7, pp. 4336-4341.
Koch, et al., “A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody”, Immunogenetics (1986), vol. 23, No. 5, pp. 322-325.
Muscari, et al., “Association of Serum C3 Levels With the Risk of Myocardial Infarction”, American Journal of Medicine (1995), vol. 98, No. 4, pp. 357-364.
Harrison et al., “Structure of C3f, a Small Peptide Specifically Released during Inactivation of the Third Component of Complement”, Component (1988), vol. 5, No. 1, pp. 27-32.
Richter et al, Composition of the peptide fraction in human blood plasma: database of circulating human peptides, J. Chrom. B. Biomed. Sci. Appl., 726, 1-2, (1999), pp. 25-35.
Takahashi et al, Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody, Clin. Chem., 45, 8, (1999), pp. 1307-1311.
Jackowski George
Marshall John
Thatcher Brad
Vrees Tammy
Yantha Jason
Cook Lisa V
Le Long V.
McHale & Slavin P.A.
Nanogen Inc.
LandOfFree
Biopolymer marker indicative of disease state having a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biopolymer marker indicative of disease state having a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biopolymer marker indicative of disease state having a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2762635